ES2638057B1 - Tratamiento de la demencia con agonistas cannabinoides - Google Patents

Tratamiento de la demencia con agonistas cannabinoides Download PDF

Info

Publication number
ES2638057B1
ES2638057B1 ES201730284A ES201730284A ES2638057B1 ES 2638057 B1 ES2638057 B1 ES 2638057B1 ES 201730284 A ES201730284 A ES 201730284A ES 201730284 A ES201730284 A ES 201730284A ES 2638057 B1 ES2638057 B1 ES 2638057B1
Authority
ES
Spain
Prior art keywords
jwh
pentyl
methyl
methanone
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201730284A
Other languages
English (en)
Spanish (es)
Other versions
ES2638057A1 (es
Inventor
Rafael RODRÍGUEZ PUERTAS
Iván MANUEL VICENTE
Laura LOMBARDERO ITURRIZAGA
Alberto LLORENTE OVEJERO
Marta MORENO RODRÍGUEZ
Jonatan MARTÍNEZ GARDEAZABAL
Estibaliz GONZÁLEZ DE SAN ROMÁN MARTÍN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of the Basque Country
Original Assignee
University of the Basque Country
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of the Basque Country filed Critical University of the Basque Country
Priority to ES201730284A priority Critical patent/ES2638057B1/es
Publication of ES2638057A1 publication Critical patent/ES2638057A1/es
Priority to PCT/EP2018/054525 priority patent/WO2018158150A1/en
Priority to EP18707035.4A priority patent/EP3589322A1/en
Priority to US16/489,110 priority patent/US20200016163A1/en
Priority to JP2019547448A priority patent/JP2020509043A/ja
Application granted granted Critical
Publication of ES2638057B1 publication Critical patent/ES2638057B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES201730284A 2017-03-02 2017-03-02 Tratamiento de la demencia con agonistas cannabinoides Active ES2638057B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201730284A ES2638057B1 (es) 2017-03-02 2017-03-02 Tratamiento de la demencia con agonistas cannabinoides
PCT/EP2018/054525 WO2018158150A1 (en) 2017-03-02 2018-02-23 Treatment of dementia with cannabinoid agonists
EP18707035.4A EP3589322A1 (en) 2017-03-02 2018-02-23 Treatment of dementia with cannabinoid agonists
US16/489,110 US20200016163A1 (en) 2017-03-02 2018-02-23 Treatment of dementia with cannabinoid agonists
JP2019547448A JP2020509043A (ja) 2017-03-02 2018-02-23 カンナビノイドアゴニストによる認知症の治療

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201730284A ES2638057B1 (es) 2017-03-02 2017-03-02 Tratamiento de la demencia con agonistas cannabinoides

Publications (2)

Publication Number Publication Date
ES2638057A1 ES2638057A1 (es) 2017-10-18
ES2638057B1 true ES2638057B1 (es) 2018-10-01

Family

ID=60043443

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201730284A Active ES2638057B1 (es) 2017-03-02 2017-03-02 Tratamiento de la demencia con agonistas cannabinoides

Country Status (5)

Country Link
US (1) US20200016163A1 (cg-RX-API-DMAC10.html)
EP (1) EP3589322A1 (cg-RX-API-DMAC10.html)
JP (1) JP2020509043A (cg-RX-API-DMAC10.html)
ES (1) ES2638057B1 (cg-RX-API-DMAC10.html)
WO (1) WO2018158150A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512409A (ja) 2018-12-14 2022-02-03 ナチュラル イクストゥラクション システムズ，エルエルシー アニオン性カンナビノイド分子と関連する組成物および方法
WO2021084523A2 (en) * 2019-10-31 2021-05-06 Radient Technologies Innovations Inc. Enhancing lifestyle of memory impaired patients using cbd
WO2021097163A1 (en) * 2019-11-14 2021-05-20 Natural Extraction Systems, LLC Pharmaceutical compositions comprising cannabinoid anions
WO2022026960A1 (en) 2020-07-31 2022-02-03 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
PL2606032T3 (pl) * 2010-08-20 2015-07-31 Univ Washington Through Its Center For Commercialization Kompozycja i sposoby terapii glejakaep

Also Published As

Publication number Publication date
US20200016163A1 (en) 2020-01-16
EP3589322A1 (en) 2020-01-08
ES2638057A1 (es) 2017-10-18
WO2018158150A1 (en) 2018-09-07
JP2020509043A (ja) 2020-03-26

Similar Documents

Publication Publication Date Title
ES2547916T3 (es) Terapia de combinación de inhibidores de mTOR/JAK
US12060327B2 (en) Psychotropic agents and uses thereof
CN102159541B (zh) 抗癌口服制剂
PT2531191E (pt) Ligandos sigma para utilização na prevenção e/ou tratamento da dor pós-operatória
BR112020012629A2 (pt) estimulantes de sgc
HRP20090565T1 (hr) Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
US20230150936A1 (en) Analogs of n,n,n-trimethyl-4-phosphoryloxytryptamine
ES2638057A1 (es) Tratamiento de la demencia con agonistas cannabinoides
EP4735441A1 (en) Pyrrolopyridine compounds for the treatment of mental illnesses
JP2025531219A (ja) 女性における鬱を処置するための組成物及び方法
CN110944630B (zh) 精神药剂及其用途
US11377421B2 (en) Psychotropic agents and uses thereof
EP3307724B1 (en) (z)-2-(1h-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile derivatives and related compounds with lysosome inhibitory and anti-mitotic activity for treating hyperproliferative diseases
JP2010509389A (ja) 化学療法剤により誘起された末梢神経毒性の処置に有効なピロロ［１，２−ａ］イミダゾールジオン
JP2024519065A (ja) 向精神薬とその用途
KR20250141162A (ko) 무쾌감증 치료를 위한 조성물 및 방법
HK40113339A (en) Psychotropic agents and uses thereof
KR20250046197A (ko) 티오벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
HK40020365B (en) Psychotropic agents and uses thereof
JP2025524204A (ja) 記憶及び認知を改善するための組成物及び方法
RU2407744C2 (ru) Лиганды альфа-адреноцепторов, допаминовых, гистаминовых, имидазолиновых и серотониновых рецепторов и их применение

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2638057

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20181001